

1 **Methodological considerations on selection of stable reference genes for RT-**
2 **qPCR in the neonatal rat brain in hypoxia and hypothermia.**

3 4 M. Bustelo^{a, b, c, d}, M.A. Bruno^c, C.F. Loidl^{c, d}, H.W.M. Steinbusch^b, A.W.D. Gavilanes^{a, e}, D.L.A. van den Hove^{b, f} *

5 a. Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, the Netherlands

6 b. Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Maastricht
7 University, Maastricht, the Netherlands

8 c. Instituto de Ciencias Biomédicas, Facultad de Ciencias Médicas, Universidad Católica de Cuyo, San Juan, Argentina

9 d. Laboratorio de Neuropatología Experimental, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis”
10 (IBCN), Facultad de Medicina, Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina

11 e. Instituto de Investigación e Innovación de Salud Integral, Facultad de Ciencias Médicas, Universidad Católica de
12 Santiago de Guayaquil, Guayaquil, Ecuador

13 f. Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany

14

15 * Corresponding author

16 E-mail: d.vandenhove@maastrichtuniversity.nl (DVDH)

17

18 **Abstract**

19 Real-time reverse transcription PCR (qPCR) normalized to an internal reference gene (RG), is a frequently
20 used method for quantifying gene expression changes in neuroscience. Although RG expression is assumed
21 to be constantly independent of physiological or experimental conditions, several studies have shown that
22 commonly used RGs are not expressed stably. The use of unstable RGs has a profound effect on the
23 conclusions drawn from studies on gene expression, and almost universally results in spurious estimation
24 of target gene expression. Approaches aimed at selecting and validating RGs often make use of different
25 statistical methods, which may lead to conflicting results. The present study evaluates the expression of 5
26 candidate RGs (*Actb*, *Pgk1*, *Sdha*, *Gapdh*, *Rnu6b*) as a function of hypoxia exposure and hypothermic
27 treatment in the neonatal rat cerebral cortex –in order to identify RGs that are stably expressed under these
28 experimental conditions– and compares several statistical approaches that have been proposed to validate
29 RGs. In doing so, we first analyzed the RG ranking stability proposed by several widely used statistical
30 methods and related tools, i.e. the Coefficient of Variation (CV) analysis, GeNorm, NormFinder,

31 BestKeeper, and the ΔCt method. Subsequently, we compared RG expression patterns between the various
32 experimental groups. We found that these statistical methods, next to producing different rankings per se,
33 all ranked RGs displaying significant differences in expression levels between groups as the most stable
34 RG. As a consequence, when assessing the impact of RG selection on target gene expression quantification,
35 substantial differences in target gene expression profiles were observed. As such, by assessing mRNA
36 expression profiles within the neonatal rat brain cortex in hypoxia and hypothermia as a showcase, this
37 study underlines the importance of further validating RGs for each new experimental paradigm considering
38 the limitations of each selection method.

39 **Keywords:** Reference genes, QPCR, Neonatal Hypoxia-Ischemia.

40

41 **Abbreviations:**

42 qPCR real-time reverse transcription PCR

43 RG reference gene

44 *Actb* beta-actin

45 *Pgk1* phosphoglycerate kinase 1

46 *Sdha* succinate dehydrogenase complex flavoprotein subunit A

47 *Gapdh* glyceraldehyde-3-phosphate dehydrogenase

48 *Rnu6b* U6 small nuclear RNA

49 18S rRNA 18S ribosomal RNA

50 *Hprt* hypoxanthine-guanine phosphoribosyltransferase

51 *B2m* beta-2-micro-globulin

52 *Tubb5* tubulin beta 5

53 *Ppia* peptidylprolyl isomerase A

54 *Ywhaz* tyrosine 3/tryptophan 5-monooxygenase activation protein zeta polypeptide

55 *Pgk1* phosphoglycerate kinase 1

56 *Tbp* TATAA-box binding protein

57 *Arbp* acidic ribosomal phosphoprotein P0

58 *Gusb* beta-glucuronidase

59 *Ckb* brain creatine kinase

60 *Rpl13a* ribosomal protein L13A
61 *Pbg-d* porphobilinogen deaminase
62 *Cypa* cyclophilin
63 *Rest* repressor element 1-silencing transcription factor
64 *Bad* BCL2/BCL-XL-associated death promoter
65

66 Introduction

67 In qPCR analysis, reference genes (RGs) with stable expression levels are essential internal controls for
68 relative quantification of mRNA expression. RGs normalize variations of candidate gene expression under
69 different conditions (1,2). The ideal RG should be expressed at constant levels regardless of e.g.
70 experimental conditions, developmental stages or treatments (3,4), and should have expression levels
71 comparable to that of the target gene (5). Nevertheless, increasing evidence suggests that the expression of
72 commonly used RGs often varies considerably under different experimental conditions, as reviewed
73 previously (6,7). The choice of unstable RGs for the normalization of qPCR data may give rise to inaccurate
74 results, concomitant with potential expression changes in genes of interest being easily missed or
75 overemphasized. Thus, the identification of stable RGs is a prerequisite for reliable qPCR experiments (9–
76 11).

77
78 RG selection should be performed using the same samples that will be compared when looking at genes of
79 interest. For this purpose, several statistical methods have been proposed, i.e. GeNorm (12), qBase (13),
80 BestKeeper (14), NormFinder (15), Coefficient of Variation (CV) analysis (16), and the comparative ΔCt
81 method (17). These statistical methods rank the stability of the candidate RGs based on a unique set of
82 assumptions and associated algorithms. As a result, the predictions of these methods can differ significantly
83 based on the method used, potentially leading to conflicting results. This observation has been frequently
84 made, but still seems to be systematically ignored in recent validation studies.

85
86 To address this issue, several approaches that make use of several statistical approaches at the same time,
87 have been proposed, including i) a weighted rank (18–20), an approach that is compromised by the fact that
88 it does not consider the strengths and drawbacks of each method for a given experimental setting; ii) the

89 “Geometric mean rank” that uses the average of the stability ranks across different methods yielding an
90 overall ranking (12,21); as well as iii) an integrated approach (22), including a first selection step making
91 use of the CV analysis (eliminating genes with $CV > 50\%$), and subsequently ranking the remaining genes
92 using GeNorm.

93

94 In the present study, we compared these methods, on the evaluation of the stability of 5 candidate RGs in
95 a murine model of perinatal asphyxia and therapeutic hypothermia. Perinatal asphyxia is a clinical condition
96 defined as oxygen deprivation that occurs around the time of birth and may be caused by perinatal events
97 such as placental abruption, cord-prolapse, or tight nuchal cord, limiting the supply of oxygenated blood to
98 the fetus (23). Recently, hypothermia has emerged as the standard of care for perinatal asphyxia. Although
99 this treatment has been demonstrated to be effective in reducing mortality and long-term consequences of
100 perinatal asphyxia, the underlying mechanisms of this therapy are still not completely understood (24–28).
101 Assessing gene expression changes in the neonatal hypoxic-ischemic brain may be of added value in order
102 to further decipher the mechanism of perinatal asphyxia and to increase the effectiveness of therapeutic
103 hypothermia and related therapies. Here, we used a murine perinatal hypoxic-ischemic encephalopathy
104 model (29–31) to address the abovementioned problems in RG selection and qPCR normalization. Several
105 *in vivo* and *in vitro* studies on hypoxia, making use of qPCR, have been reported (19,32–39), indicating
106 that hypoxia significantly impacts the expression of various commonly used RGs. Although some of these
107 studies use the same or similar hypoxia models, the results vary substantially across studies, emphasizing
108 the need to publish these validation studies prior or parallel to reporting qPCR results.

109

110 We selected five candidate RGs based on published RG validation studies involving hypoxia (Table 1).
111 Subsequently, we applied various validated methodological and statistical methods to evaluate the effects
112 of anoxia and hypothermia on the expression stability of the candidate RGs. To evaluate the impact of the
113 resulting RG selection, we assessed the expression levels of the Repressor Element 1-Silencing
114 Transcription Factor (*Rest*), a gene that has been shown to be upregulated by hypoxic-ischemic injury in
115 the peri-infarct cortex of adult rats following transient focal ischemia induced by middle cerebral artery
116 occlusion (MCAO) (40). Moreover, the proapoptotic gene BCL2/BCL-XL-associated death promoter
117 (*Bad*), a gene that has been shown to be up-regulated by hypoxia in the MCAO rat model, was assessed

118 (41). This study provides a basis for the selection of RGs and useful guidelines for future gene expression
119 studies, in particular regarding studies on developmental hypoxic insults.

120 **Table 1. List of published RG validation studies involving hypoxia.**

121

Species	Hypoxia model and tissue	Evaluated HKG	Method	Most Stable HKG	Reference
Rat	P7. Hypoxia-ischemia model. Brain cortex	<i>Ppia, Hprt, Pgk1, Rp190, B2m, Tbp, Gapdh.</i>	GeNorm Normfinder	0h: <i>Hprt</i> and <i>Pgk1</i> 3h: <i>B2m</i> , <i>Hprt</i> , and <i>Ppia</i> 12h: <i>Pgk1</i> , <i>Ppia</i> , and <i>Rp190</i>	35
	Adult. Chronic intermittent hypoxia. Hippocampus, hypothalamus, and frontal and temporal cortices	<i>Actb, B2m, Gapdh, Hprt, 18S rRNA.</i>		<i>Dependent on the brain area</i> <i>Actb</i> , <i>B2m</i> , <i>Gapdh</i> , <i>Hprt</i> were stable.	36
	Neural stem cell culture. Normoxic (20% O2) or hypoxic condition (0.3% O2)	<i>Ckb, Hprt, Gapdh, Actb, Rp113a, Pbg-d, Pha.</i>	geNorm and NormFinder BestKeeper	<i>Hprt</i> and <i>Rp113a</i>	37
Mice	- Adult C57 mice. MCAO. Brain cortex - Neuroblastoma cell line. OGD/R	<i>Hprt, Actb, Sdha, Gapdh, 18SrRNA, Cypa.</i>	geNorm, NormFinder, BestKeeper and RefFinder	- MCACO: <i>Hprt</i> and <i>18SrRNA</i> - OGD/R: <i>Actb</i> and <i>Cypa</i>	38
	3, 6, and 12 months APP23 mice. 48h hypoxic chamber. Frontal cortex and hippocampus	Selected from a list of 10 reference targets	qBase ⁺	<i>Gapdh, Actb, B2m</i> , and <i>Pgk1</i>	39
	P9. Hypoxia-ischemia model. Primary mixed glial cultures were prepared from P1 to P3 mice of both sexes.	<i>Ywhaz, Gapdh, Gusb, 18S rRNA</i>	GenEx Software (v5.1.1), which uses GeNorm and NormFinder	<i>Ywhaz</i>	40
Human	P9. Unilateral HI. Hippocampus, striatum, and cortex	<i>Gapdh, Tubb5, Ppia, Actb, Ywhaz, 18S rRNA, B2m, Pgk1, Tbp, Arbp, Gusb, Hprt</i>	Mouse Endogenous Control Gene Panel (TATAA Biocenter) and NormFinder	<i>Pgk1</i> and <i>B2m</i>	41
	P7, Hypoxia-ischemia model P10. Unilateral HI+ hypoxia + normothermia or hypothermia. Forebrain and diencephalon	<i>Gapdh, Actb</i>	BestKeeper	<i>Actb</i>	42
	< 1 year. Post-mortem samples of sudden infant death syndrome and control cases. Brainstem medulla oblongata	<i>Gapdh, Gusb, Hmbs, Sdha, Ubxrn6.</i>	GeNorm	<i>Sdha</i> and <i>Ubxrn6</i>	43
	Adult. Acute ischemic stroke patients. Whole blood	<i>Snoord49a, Snoord49b, Rnu6b, hsa-miR-423-5p, hsa-miR-103, and hsa-miR-191</i>	geNorm and Normfinder	<i>Rnu6b</i>	44

123

124 **Methods**

125 **Ethics statement**

126 This study was carried out in accordance with the recommendations in the Guide for the Care and Use of
127 Laboratory Animals of the National Institute of Health of Argentina. The protocol was approved by the
128 Biomedical Ethics Committee of Universidad Católica de Cuyo, San Juan, Argentina and by the Ethical
129 Committee of CICUAL: “Institutional Committee for the Use and Care of Laboratory Animals” (Resolution
130 no. 2079/07), Facultad de Medicina, Universidad de Buenos Aires, Argentina. Appropriate actions were
131 taken to minimize the number of animals used and their suffering, pain, and discomfort.

132

133 **Hypoxic-ischemic injury animal model**

134 Severe acute PA was induced using a model of hypoxia-ischemia as described previously (26-28). Briefly,
135 albino Sprague-Dawley rats were kept under standard laboratory conditions at 24°C with light-dark cycles
136 of 12:12 hours, and food and water present ad libitum. Fifteen timed-pregnant Sprague-Dawley rats were
137 used. The first group of offspring studied consisted of normally delivered naive pups that were used as
138 controls (CTL; n=6). After vaginal delivery of the first pup, pregnant dams were euthanized by decapitation
139 and immediately hysterectomized. All full-term fetuses, still inside the uterus, were subjected to asphyxia
140 by transient immersion of both uterine horns in a saline bath for 20 min at either 37°C (perinatal asphyxia
141 in normothermia, PA, n=6) or 15°C (perinatal asphyxia in hypothermia, [HYPPA]; n=6). After asphyxia,
142 the uterine horns were opened, pups were removed, dried of delivery fluids, and stimulated to breathe, and
143 their umbilical cords were ligated. After recovery, one group of PA animals was placed on a cooling pad at
144 8°C for 15 minutes for hypothermic treatment (PAHYP, n=6), while hypothermic control animals (HYP,
145 n=6) received the same treatment. After 15 minutes of exposure to the cold environment the core
146 temperature of the newborns was measured with a rectal probe (mean temperature: 20.1°C; n=8). The pups
147 were subsequently placed under a heating lamp for recovery after which they were placed with a
148 surrogate mother. Time of asphyxia was measured as the time elapsed from the hysterectomy up to the
149 recovery from the water bath. Pups that adjusted to the following parameters were included: 1.
150 Occipitocaudal length > 41mm, 2. Weight > 5g.

151

152 **Total RNA extraction and reverse transcription cDNA**
153 **synthesis**

154 Animals were sacrificed by quick decapitation 24 h post treatment. The brain cortex was isolated, snap-
155 frozen in liquid nitrogen, ground into powder with pestle and mortar cooled in liquid nitrogen and then
156 stored at -80 °C. Total RNA was isolated from about 80 mg tissue powder using TRIzol® (Invitrogen Life
157 Technologies, USA) following the manufacturer's instructions. The residual DNA was removed by the
158 TURBO DNA free kit (Ambion Inc., UK). Yield and purity of RNA was determined by the NanoDrop ND-
159 1000 spectrophotometer (Nanodrop technologies, USA). RNA samples with an absorbance ratio OD
160 260/280 between 1.9–2.2 and OD 260/230 greater than 2.0 were used for further analysis. RNA integrity
161 was assessed using agarose gel electrophoresis. One microgram of RNA from each sample was reverse
162 transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to
163 the manufacturer's instructions. cDNA was stored at -20 °C for future use. For qPCR analysis, each cDNA
164 sample was diluted 20 times with nuclease-free water.

165

166 **Real-time PCR**

167 Real-time PCRs were conducted using the LightCycler® 480 Multiwell Plate 96 (Roche, Mannheim,
168 Germany) containing 1µM of each primer. For each reaction, the 20 µl mixture contained 1 µl of diluted
169 cDNA, 5 pmol each of the forward and reverse primers, and 10 µl 2 × SensiMix SYBR No-ROX Kit
170 (Bioline, UK). The amplification program was as follows: 95°C for 30 sec, 40 cycles at 95°C for 15 sec,
171 and 60°C for 15 sec, and 72°C for 15 sec. After amplification, a thermal denaturing cycle was conducted
172 to derive the dissociation curve of the PCR product to verify amplification specificity. Reactions for each
173 sample were carried out in triplicate. qPCR efficiencies in the exponential phase were calculated for each
174 primer pair using standard curves (5 ten-fold serial dilutions of pooled cDNA that included equal amounts
175 from the samples set). The mean threshold cycle (Ct) values for each serial dilution were plotted against
176 the logarithm of the cDNA dilution factor and calculated according to the equation $E = 10(-1/slope) \times 100$,
177 where the slope is the gradient of the linear regression line.

178

179 Reference gene selection

180 Based on their common usage as endogenous control genes in previous studies (Table 1), five candidate
181 RGs were analyzed, i.e., *Actb*, *Pgk1*, *Gapdh*, *Sdha*, *Rnu6b*. These genes represent commonly used
182 endogenous control genes chosen from the relevant literature and have been previously validated in rat,
183 mouse and human brain tissues exposed to hypoxia. The selected RGs belong to different molecular
184 pathways to minimize the risk of co-regulation between genes. The primers were designed from nucleotide
185 sequences identified using NCBI BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). *Rnu6b* TaqMan
186 MicroRNA Assay (*Rnu6b*) was commercially available (Thermo Fisher Scientific, Product number:
187 4427975-001093). All other primers were ordered from Thermo Fisher Scientific with their certificates of
188 analysis. The primer characteristics of nominated RGs are listed in Table 2. The primer sequences (5'-3')
189 of the target genes were as follows:

190 *Rest*; - F, AACTCACACAGGAGAACGCC - R, GAGGTTAGGCCGTTGTGA.

191 *Bad*; - F, GCCCTAGGCTTGAGGAAGTC - R, CAAACTCTGGATCTGGAACA.

192

193 **Table 2. List of RGs investigated by qPCR.**

Gene symbol	Gene name	Accession number	Function	Primer sequence (5'-3')	Product length (bp)	Efficiency (%)
<i>Actb</i>	Beta-actin	NM_031144	Cytoskeletal structural protein	F: CCCGCGAGTACAACCTTCTTG R: GTCATCCATGGCGAACTGGTG	71	104.3
<i>Pgk1</i>	Phosphoglycerate kinase 1	NM_053291.3	Glycolytic enzyme	F: GTCGTGATGAGGGTGGACTT R: AACCGACTTGGCTCCATTGT	120	99.75
<i>Sdha</i>	Succinate dehydrogenase complex flavoprotein subunit A	NM_130428.1	Catalytic subunit of succinate-ubiquinone oxidoreductase	F: AGCCTCAAGTTGGAAAGG R: CCGCAGAGATCGTCCATACA	102	102.75
<i>Gapdh</i>	Glyceraldehyde-3-phosphate dehydrogenase	NM_017008.4	Membrane fusion, microtubule bundling, cell death, and neurite outgrowth	F: AAGGGCTCATGACCACAGTC R: GTGAGCTTCCCATTCTAGCTC	143	92.1
<i>Rnu6b</i>	RNU6-2; U6 small nuclear RNA	NR_002752	ncRNAs	CGCAAGGATGACACGCAAATTG TGAAGCGTTCCATATTGTT	64	93.95

194

195 **Analysis of expression stability using multiple statistical approaches.** To assess the stability of
196 candidate RGs, five statistical methods, each with unique characteristics, were used: GeNorm, BestKeeper,
197 NormFinder, Coefficient of Variation analysis, and the comparative ΔCt method. Ct values were converted
198 to non-normalized relative quantities according to the formula: $2^{-\Delta Ct}$. CV analysis, GeNorm and

199 NormFinder calculations are based on these converted quantities, whereas BestKeeper and the ΔCt method
200 make use of raw Cq values.

201

202 **Impact of selection of RGs on gene expression normalization.** The impact of RG selection on gene
203 expression quantification was assessed via examining the expression of *Rest* and *Bad*. Six gene expression
204 normalizing strategies were used to represent the least and most stable reference genes. The relative
205 expression profiles of *Rest* and *Bad* were determined and normalized with all tested RGs. Relative fold
206 changes in gene expression were calculated using the DDCt and Pfaffl methods. Data was expressed as
207 mean \pm standard error of the mean (SEM) from six independent samples/group with triple qPCR reactions.
208 One-way analysis of variance (ANOVA) test was applied to analyze significant differences between
209 conditions for each house-keeping gene. Differences were reported as statistically significant when $p < 0.05$.
210 GraphPad Prism 6 (GraphPad Software, USA) was used for statistical procedures and graph plotting.

211

212 **Results**

213 **qPCR**

214 Pilot assays were performed to optimize cDNA and primer quantities. A total of 0.9 mg of RNA that was
215 previously treated with DNase was used for the reverse transcription reaction in a total volume of 40ml.
216 One microliter of the resulting cDNA was used for the qPCR reaction. Each gene amplification was
217 analyzed, and a melting curve analysis was performed, showing a single peak indicating the temperature of
218 dissociation. Efficiencies are shown in Table 2. All Ct values were between 17.0 and 33.0.

219 **Coefficient of Variation analysis**

220 We calculated the raw expression profiles of RGs as changes of Ct values across groups and ranked the
221 gene stability according to the CV. The CV analysis is a descriptive statistical method where the Ct values
222 of all candidate RGs across samples are first linearized ($2^{-\text{Cq}}$). Next, the CV for each gene across all samples
223 was calculated and expressed as a percentage. The CV estimates the variation of a gene across all samples
224 taken together, and, therefore, a lower CV value indicates higher stability. This analysis on the cortical
225 samples revealed *Gapdh* as the most stable RG, and *Actb* as the least stable RG. This method however does

226 not consider the variation across different treated groups; hence, CV analysis alone cannot determine the
227 best set of RGs.

228

229 **Fig 1. Variability of the raw Ct values of the five candidate RGs under different experimental**
230 **conditions.** a. Relative quantities without normalization to any RG using cerebral cortex samples (n=30).
231 The boxes encompass the 25th to 75th percentiles, whereas the line in the box represents the mean. Whisker
232 caps denote the maximum and minimum values. b. CV analysis of the linearized Ct values.

233

234 To assess if the mean mRNA levels across groups were significantly different from one another, a One-
235 way ANOVA was used. The results demonstrated that variations in the Ct values for the different treatments
236 were different for all candidate RGs. Four of the five genes tested (*Sdha*, *Rnu6b*, *Pgk1*, *Actb*) showed
237 significant variation in mRNA levels across different treatments (Fig 2). Only *Gapdh* showed no significant
238 changes. These results, making use of the raw expression profiles of the RGs, suggest that the various
239 experimental conditions were associated with changes in RG expression levels that, as such, could skew
240 the normalized profile of target genes. As a result, RG selection without accounting for potential expression
241 differences between conditions is accompanied by a significant bias in the results and their interpretation.
242 Hence, it is of utmost importance to validate the stability of RGs prior to normalization in gene expression
243 studies.

244

245 **Fig 2. Expression profiles of RG expressed as Cp across the experimental conditions.** a. *Actb*, b. *Pgk1*,
246 c. *Sdha*. d. *Gapdh*, e. *Rnu6b*. Results are expressed as the Mean \pm SEM for each treatment. One-way
247 ANOVA was performed to asses differences between the means of all groups. Statistical significance is
248 denoted by *p* values: **p*<0.05, ***p*<0.01, ****p*<0.001.

249

250 Next, to identify the optimal RG(s), the expression stability of candidate RGs was analyzed using four well
251 known statistical methods (Table 3).

252

253

254

255

256 **Table 3. Candidate RG expression stability.**

Rank	GeNorm		NormFinder		BestKeeper			Δ Ct method		Comprehensive ranking			
	Gene	M	Gene	S	Gene	Cv (%Ct)	SD (±Ct)	r	Gene	Mean SD	Geomean	Rank	Gene
1	<i>Pgk1</i>	0.596	<i>Actb</i>	0.222	<i>Pgk1</i>	2.17	0.53	0.825	<i>Pgk1</i>	1.41	1.5	1	<i>Pgk1</i>
2	<i>Actb</i>	0.599	<i>Sdha</i>	0.298	<i>Actb</i>	2.83	0.55	0.819	<i>Sdha</i>	1.45	2	2	<i>Actb</i>
3	<i>Sdha</i>	0.782	<i>Pgk1</i>	0.298	<i>Sdha</i>	1.54	0.32	0.814	<i>Actb</i>	1.53	2.5	3	<i>Sdha</i>
4	<i>Gapdh</i>	1.053	<i>Gapdh</i>	1.736	<i>Gapdh</i>	1.84	0.44	0.614	<i>Gapdh</i>	2.00	4	4	<i>Gapdh</i>
5	<i>Rnu6b</i>	1.923	<i>Rnu6b</i>	3.17	<i>Rnu6b</i>	1.97	0.57	0.106	<i>Rnu6b</i>	3.23	5	5	<i>Rnu6b</i>

Stability was ranked by GeNorm, NormFinder, BestKeeper and Δ CT average STDEV. The comprehensive ranking was based on the geometric mean of the gene rank. Candidates are listed from top to bottom in order of decreasing expression stability. (SD [\pm Ct]: standard deviation of the Ct; CV [% Ct]: coefficient of variance expressed as a percentage of the Ct level; geomean: geometrical mean).

257

258 First, a GeNorm analysis was performed on all five candidate genes. GeNorm calculates stability value (M)
 259 based on pairwise variation of every two genes. The rationale is that if two genes vary similarly across all
 260 samples, then they are the most stable RGs for that dataset. A limitation of this method is that if two genes
 261 are regulated in the same direction by one or more experimental conditions, those will often be assumed to
 262 be the most stable. In our analysis, except for *Rnu6b*, which presented the highest M-value (M=1.923), all
 263 of the other candidate RGs presented M-values lower than 1.5, which is considered to be the cut-off for
 264 suitability. Based on this analysis for the neonatal cortex, the most stable RGs were *Pgk1* and *Actb*. This is
 265 in stark contrast to the CV analysis, that showed those genes as the least stable ones (higher CV), and to
 266 the expression profiles that showed inter-group differences.

267

268 NormFinder calculates the stability score (S) based on the inter- and intra-group variation. However, it has
 269 been reported that including genes with high overall variation can affect the stability ranking of all genes
 270 with this method (22). This algorithm can potentially be improved after identifying and removing genes
 271 with high overall variation.. *Actb*, *Sdha* and *Pgk1* were the most stable RGs, presented stability values lower
 272 than 0.3. *Gapdh* (SV=1.736) and *Rnu6b* (SV=3.17) were the least stable.

273

274 BestKeeper uses the cycle threshold (Ct) values to calculate a standard deviation (SD), coefficient of
 275 variance (CV), and Pearson correlation coefficient (r) for each gene. Lower SD and CV values indicate
 276 more stable gene expression, and genes that exhibit a SD in Ct values above 1.0 should be eliminated and
 277 regarded as unreliable controls. Then, the remaining RG are ranked according to r values, with a higher r
 278 value indicating more stable gene expression. None of the genes analyzed were excluded for having SD

279 above 1. The most stable RG was *Pgk1* ($r=0.825$), while *Rnu6b* was considered the least stable gene
280 ($r=0.106$). The ranking obtained from this analysis was the same as the one obtained with GeNorm.

281

282 The Δ -Ct method works on the same rationale as GeNorm but calculates the stability value (mean SD)
283 differently; it is calculated as the average standard deviation of the Ct value differences that the gene
284 exhibits with other genes. Using this method, the ranking was similar to previous rankings. The most stable
285 RGs were *Pgk1* (Av. SD=1.41) and *Sdha* (Av. SD=1.45), and the least stable *Rnu6b* (Av. SD=3.23). The
286 overall ranking depicted in Table 3 was based on the geometric mean of the previous gene ranks. This
287 ranking indicates that for this tissue and treatment, the most stable RG was *Pgk1*.

288

289 Impact of RG selection on target gene expression profiles

290 The impact of RG selection on gene expression quantification was assessed by examining the expression
291 of *Rest* and *Bad*. These genes have shown to be influenced by hypoxia and hypothermia. Five gene
292 expression normalizing strategies were used to select the least and most stable RGs, and the best
293 combination of two genes, *Actb/Pgk1* (Fig 3). Expression values were calculated relative to expression in
294 control animals, using both the $\Delta\Delta$ Ct method (Livak & Schmittgen, 2001) and the primer efficiency method
295 (Pfaffl, 2001, Fig 3). Results were similar using Livak or Pfaffl methods. As expected, even when the
296 general pattern of target gene expression was similar for most of the RGs across treatments, target gene
297 expression levels were different depending on the RG used for normalization causing differences in the
298 significance level of the expression patterns.

299

300 **Fig 3. Evaluation of the impact of selection of RG on gene expression normalization.** Expression
301 profiles of *Rest* and *Bad* normalized by different strategies. Arithmetic mean values and standard deviations
302 were obtained from three bioreplicates.

303

304 Discussion

305 The selection of RGs in qPCR experiments has an enormous impact on the reliability and interpretation of
306 results in gene expression studies making it a crucial yet often understated process. It is now recognized

307 that normalization of qPCR results against a single RG is likely to be inadequate and that normalization
308 against a panel of RGs containing at least three stable RGs is preferred. However, for most of the RGs used
309 in published qPCR studies, no thorough investigation of their variation over experimental conditions has
310 been performed and/or reported (48). Many researchers continue to use a single, unvalidated RG to
311 normalize data.

312

313 The majority of studies where assessment of the RGs' stability is included make use of statistical tools like
314 GeNorm, BestKeeper, NormFinder, CV analysis, and the comparative ΔCt method. Each of these methods
315 determines the stability based on a set of assumptions and calculations, and has its own limitations. In
316 general, methods that rely on pairwise variation (GeNorm and Pairwise ΔCt method) are influenced by the
317 expression pattern of all genes making their ranking inter-dependent. The CV analysis does not take the
318 variation between groups into account, hence alone it cannot determine the best (set of) RG(s), but it can
319 be used as a first filter to discard genes with high overall variance. Moreover, except for the CV analysis,
320 the presence of genes with high overall variation impact upon the ranking of all these methods.

321

322 As a result, the selection of stable RGs varies significantly depending on the method used making the choice
323 of the validation method a critical step in qPCR assays. In our study, using Geomean, *Pgk1* was the most
324 stable gene across treatments, while *U6* and *Gapdh* were ranked as most variable. This is in stark contrast
325 to the CV% Analysis and intergroup ANOVA Ct variations that indicated that *Gapdh* was the most stable
326 gene among groups, and *Actb* the least stable.

327

328 Using any of these methods alone is not sufficient in obtaining bias-free results. Generally, stability
329 validation studies have ranked the genes using Geomean, a ranking obtained from the mean rank of the
330 statistical tools used. This method does not take into account the limitations of each algorithm separately,
331 which is why it is increasingly considered an erroneous approach when validating RGs. This makes the
332 identification of the best RGs very unwieldy. Using the same statistical methods, new approaches have
333 been proposed, such as the "Integrated approach" (22) that has shown to provide a more accurate estimate
334 of RG stability. It is advisable to devise integrated approaches based on suitability for each experimental
335 setting.

336

337 Although we analyzed a small set of candidate RGs, we found differences in the stability rankings obtained
338 with the different methodologies, and the associated bias was reflected in our target gene quantification.
339 Our study emphasizes the necessity of validating RGs previous to assessing target gene qPCR data, and the
340 importance of choosing the right set of statistical methods for doing so. Such an approach would lead to
341 more accurate and reproducible expression assessment.

342

343 **Funding**

344 This research was partially supported by the Sistema de Investigación y Desarrollo (SINDE) and the
345 Vicerrectorado de Investigación y Posgrado of the Universidad Católica de Santiago de Guayaquil,
346 Guayaquil, Ecuador. M. Bustelo is funded by Consejo Nacional de Investigaciones Científicas y Técnicas
347 (CONICET) of Argentina and the Foundation of Pediatrics, Maastricht University Medical Center. F. Loidl
348 is supported by Universidad de Buenos Aires (UBACyT - 20020160100150BA).

349

350 **References**

- 351 1. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc.* 2008;
- 352 2. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den hoff MJB, et al. Amplification efficiency: Linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res.* 2009;
- 353 3. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. *Biotechniques.* 2005;
- 354 4. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. *Clin Chem.* 2009;
- 355 5. Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. *BioTechniques.* 2000.
- 356 6. Bustin SA, Wittwer CT. MIQE: A Step Toward More Robust and Reproducible Quantitative PCR. *Clin Chem.* 2017;
- 357 7. Bustin SA, Benes V, Garson J, Hellemans J, Huggett J, Kubista M, et al. The need for transparency and good practices in the qPCR literature. *Nature Methods.* 2013.
- 358 8. Coulson DTR, Brockbank S, Quinn JG, Murphy S, Ravid R, Brent GB, et al. Identification of valid reference genes for the normalization of RT qPCR gene expression data in human brain tissue.

366 BMC Mol Biol. 2008;

367 9. B. K, M. R. Reference genes in real-time PCR. Journal of Applied Genetics. 2013.

368 10. Tunbridge EM, Eastwood SL, Harrison PJ. Changed relative to what? Housekeeping genes and
369 normalization strategies in human brain gene expression studies. Biological Psychiatry. 2011.

370 11. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, et al. The digital MIQE guidelines:
371 Minimum information for publication of quantitative digital PCR experiments. Clin Chem. 2013;

372 12. J V, K DP, I P, B P, N VR, A DP, et al. Accurate normalization of real-time quantitative RT-PCR
373 data by geometric averaging of multiple internal control genes. Genome Biol. 2002;

374 13. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification
375 framework and software for management and automated analysis of real-time quantitative PCR
376 data. Genome Biol. 2008;

377 14. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes,
378 differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-
379 wise correlations. Biotechnol Lett. 2004;

380 15. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-
381 PCR data: A model-based variance estimation approach to identify genes suited for normalization,
382 applied to bladder and colon cancer data sets. Cancer Res. 2004;

383 16. Boda E, Pini A, Hoxha E, Parolisi R, Tempia F. Selection of reference genes for quantitative real-
384 time RT-PCR studies in mouse brain. J Mol Neurosci. 2009;

385 17. Silver N, Best S, Jiang J, Thein SL. Selection of housekeeping genes for gene expression studies
386 in human reticulocytes using real-time PCR. BMC Mol Biol. 2006;

387 18. Perez LJ, Rios L, Trivedi P, D'Souza K, Cowie A, Nzirorera C, et al. Validation of optimal
388 reference genes for quantitative real time PCR in muscle and adipose tissue for obesity and diabetes
389 research. Sci Rep. 2017;

390 19. Kang Y, Wu Z, Cai D, Lu B. Evaluation of reference genes for gene expression studies in mouse
391 and N2a cell ischemic stroke models using quantitative real-time PCR. BMC Neurosci. 2018;

392 20. Rydbirk R, Folke J, Winge K, Aznar S, Pakkenberg B, Brudek T. Assessment of brain reference
393 genes for RT-qPCR studies in neurodegenerative diseases. Sci Rep. 2016;

394 21. Chervoneva I, Li Y, Schulz S, Croker S, Wilson C, Waldman SA, et al. Selection of optimal
395 reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics. 2010;

396 22. Sundaram VK, Sampathkumar NK, Massaad C, Grenier J. Optimal use of statistical methods to
397 validate reference gene stability in longitudinal studies Abstract : 2019;

398 23. Fattuoni C, Palmas F, Noto A, Fanos V, Barberini L. Perinatal asphyxia: A review from a
399 metabolomics perspective. *Molecules*. 2015;

400 24. Dixon K, Smith S. In neonates with hypoxic ischemic encephalopathy, is therapeutic hypothermia
401 outside of current criteria safe? A literature review. *Journal of Neonatal Nursing*. 2019.

402 25. Davidson JO, Wassink G, van den Heuvel LG, Bennet L, Gunn AJ. Therapeutic hypothermia for
403 neonatal hypoxic-ischemic encephalopathy - Where to from here? *Frontiers in Neurology*. 2015.

404 26. Shankaran S, Pappas A, McDonald SA, Vohr BR, Hintz SR, Yolton K, et al. Childhood outcomes
405 after hypothermia for neonatal encephalopathy. *Obstetrical and Gynecological Survey*. 2012.

406 27. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head
407 cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised
408 trial. *Lancet*. 2005;

409 28. Iwata O, Iwata S, Thornton JS, De Vita E, Bainbridge A, Herbert L, et al. "Therapeutic time
410 window" duration decreases with increasing severity of cerebral hypoxia-ischaemia under
411 normothermia and delayed hypothermia in newborn piglets. *Brain Res*. 2007;

412 29. Loidl CF, Gavilanes AWD, Van Dijk EHJ, Vreuls W, Blokland A, Vles JSH, et al. Effects of
413 hypothermia and gender on survival and behavior after perinatal asphyxia in rats. *Physiol Behav*.
414 2000;

415 30. Capani F, Loidl CF, Aguirre F, Piehl L, Facorro G, Hager A, et al. Changes in reactive oxygen
416 species (ROS) production in rat brain during global perinatal asphyxia: An ESR study. *Brain Res*.
417 2001;

418 31. Loidl CF, Capani F, López-Costa JJ, Selvín-Testa A, López EM, Pecci-Saavedra J. Long term
419 changes in NADPH-diaphorase reactivity in striatal and cortical neurons following experimental
420 perinatal asphyxia: Neuroprotective effects of hypothermia. *Int J Neurosci*. 1997;

421 32. Arteaga O, Revuelta M, Uriguen L, Martínez-Millán L, Hilario E, Álvarez A. Docosahexaenoic
422 Acid Reduces Cerebral Damage and Ameliorates Long-Term Cognitive Impairments Caused by
423 Neonatal Hypoxia-Ischemia in Rats. *Mol Neurobiol*. 2017;

424 33. Julian GS, De Oliveira RW, Perry JC, Tufik S, Chagas JR. Validation of housekeeping genes in the
425 brains of rats submitted to chronic intermittent hypoxia, a sleep apnea model. *PLoS One*. 2014;

426 34. Yao L, Chen X, Tian Y, Lu H, Zhang P, Shi Q, et al. Selection of housekeeping genes for
427 normalization of RT-PCR in hypoxic neural stem cells of rat in vitro. *Mol Biol Rep.* 2012;

428 35. A.A. B, Y. M, R. V, V.G. S, P. S, M. R, et al. Does Caspase-6 Have a Role in Perinatal Brain
429 Injury? *Dev Neurosci.* 2015;

430 36. Järlestedt K, Rousset CI, Faiz M, Wilhelmsson U, Stahlberg A, Sourkova H, et al. Attenuation of
431 reactive gliosis does not affect infarct volume in neonatal hypoxic-ischemic brain injury in mice.
432 *PLoS One.* 2010;

433 37. Keddy PGW, Dunlop K, Warford J, Samson ML, Jones QRD, Rupasinghe HPV, et al.
434 Neuroprotective and Anti-Inflammatory Effects of the Flavonoid-Enriched Fraction AF4 in a
435 Mouse Model of Hypoxic-Ischemic Brain Injury. *PLoS One.* 2012;


436 38. El-Kashef N, Gomes I, Mercer-Chalmers-Bender K, Schneider PM, Rothschild MA, Juebner M.
437 Validation of adequate endogenous reference genes for reverse transcription-qPCR studies in
438 human post-mortem brain tissue of SIDS cases. *Forensic Sci Med Pathol.* 2015;

439 39. L.-L. Z, X.-S. H, J.-R. L, C.-B. Z, Y.-T. W, G.-Y. Y. Lentivirus-Mediated Overexpression of
440 MicroRNA-210 Improves Long-Term Outcomes after Focal Cerebral Ischemia in Mice. *CNS*
441 *Neurosci Ther.* 2016;

442 40. Morris-Blanco KC, Kim TH, Bertogliat MJ, Mehta SL, Chokkalla AK, Vemuganti R. Inhibition of
443 the Epigenetic Regulator REST Ameliorates Ischemic Brain Injury. *Molecular Neurobiology.*
444 2018;

445 41. Yenari MA, Han HS. Neuroprotective mechanisms of hypothermia in brain ischaemia. *Nature*
446 *Reviews Neuroscience.* 2012.

a.



b.

CV Analysis		
Gene	CV%	Rank
<i>Gapdh</i>	27.89	1
<i>Sdha</i>	39.67	2
<i>Pgk1</i>	44.51	3
<i>Rnu6b</i>	46.34	4
<i>Actb</i>	47.42	5

Figure 1




Figure 2





Figure 3